 MagicMed Industries Inc merger partner Enveric Biosciences Inc NASDAQ:ENVB announced that it has received approval from the Israeli Ministry of Health to begin the Phase 12 portion of its study of its synthetic cannabidiol CBD glioblastoma treatment, EV101. The study is designed to investigate the safety and efficacy of synthetic CBD when administered alone or in combination with clomiphene, concurrently with the tumor medication temozolomide, to treat patients suffering from recurrent or progressive glioblastoma GBM. 